AFP and hepatocellular carcinoma: Furthermore, serum ANGPTL6 could effectively differentiate between the noncancer group (HCs and CHB patients) and early-stage HCC patients with serum AFP ≤ 7 ng/mL (Figure 12B and Tables S10 and S11, AUC = 0.717, 95% CI: 0.614 to 0.805) with 50.0% sensitivity and 91.9% specificity.